Filing Flows

Filing Flows › Companies › Bio Key International › Cash flow

Bio Key International cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$846K in Q2 2026 · −$4.2M over twelve months

Operating cash flow−$846K
Free cash flow−$846K
Cash conversion cycle39 days

Analysis

In Q2 2026, Bio Key International generated −$846K of operating cash flow. That is $36K more than in Q2 2025 (−$881K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$4.2M; the largest uses were operating cash flow ($4.2M), capital spending ($6K); besides operations, cash came from other financing ($2.4M), net borrowing (+) / repaid (−) ($1.0M); the cash balance fell by $896K.

Operating cash flow was −$846K against net income of −$577K. The largest differences: inventory +$666K, deferred revenue −$212K, payables −$98K.

Its cash conversion cycle was 39 days (receivables 78 + inventory 132 − payables 171).

Free cash flow

Bio Key International: free cash flow by quarterBio Key International: free cash flow by quarter−$1.3MQ3 2024−$505KQ4 2024−$840KQ1 2025−$881KQ2 2025−$1.1MQ3 2025−$1.8MQ4 2025−$358KQ1 2026−$846KQ2 2026
Operating cash flow less capital spending.
Bio Key International: operating cash flow against capital spendingBio Key International: operating cash flow against capital spendingOperating cash flowCapital spending−$1.3M$21KQ3 2024−$515K−$10KQ4 2024−$835K$5KQ1 2025−$880K$1KQ2 2025−$1.1M$1KQ3 2025−$1.8M$5KQ4 2025−$358K$0Q1 2026−$846K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$846K, Capital spending $0.

Capital allocation, year by year

Bio Key International: where the cash came from (up) and went (down), by fiscal yearBio Key International: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$9.0MFY2021: Capital spending −$42KFY2021FY2022: Operating cash flow −$6.2MFY2022: Net borrowing $2.0MFY2022: Capital spending −$82KFY2022: Acquisitions −$624K$2.0MFY2022FY2023: Operating cash flow −$3.8MFY2023: Net borrowing −$2.2MFY2023: Shares issued $4.3MFY2023: Capital spending −$1K$4.3MFY2023FY2024: Operating cash flow −$2.9MFY2024: Net borrowing $2.0MFY2024: Capital spending −$13K$2.0MFY2024FY2025: Operating cash flow −$4.7MFY2025: Net borrowing $545KFY2025: Capital spending −$12K$545KFY2025
Over these 5 years operating cash flow totalled −$26.6M; the largest uses were operating cash flow ($26.6M) and net borrowing ($2.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$1.4M
Debtnone
Net cash$1.4M
Cash runway4 months

Bio Key International is burning cash: its operations consume cash, a free cash flow of −$4.2M a year at the current rate against $1.4M of cash and investments: a runway of about 4 months before any new financing.

Where the cash came from and went

Bio Key International: sources (+) and uses (−) of cash, Q2 2026Bio Key International: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$869KOperating cash flow−$846KExchange rates−$31KOther financing$8K
Bio Key International: sources (+) and uses (−) of cash, TTM to Q2 2026Bio Key International: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$4.2MOther financing$2.4MNet borrowing (+) / repaid (−)$1.0MCash drawn (+) / kept (−)$896KExchange rates−$121KCapital spending−$6K

From profit to cash

Bio Key International: net income to operating cash flow, Q2 2026Bio Key International: net income to operating cash flow, Q2 2026Net income−$577KDepreciation & amortization$74KStock-based pay$43KReceivables$68KInventory$666KPayables−$98KAccrued liabilities$43KDeferred revenue−$212KPrepaid and other assets$6KOperating cash flow−$846K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20267813217139
Q1 2026598512221
Q4 20259313019725
Q3 20255892198-49
Q2 20254866143-29
Q1 202543119223-62
Q4 202483134418-200
Q3 20246181307-165

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026−$846K——$869K−$846K
Q1 2026−$358K——$447K−$358K
Q4 2025−$1.8M−$5K—−$655K−$1.8M
Q3 2025−$1.1M−$1K$1.0M$235K−$1.1M
Q2 2025−$880K−$1K—$858K−$881K
Q1 2025−$835K−$5K—−$2.7M−$840K
Q4 2024−$515K$10K$92K$1.4M−$505K
Q3 2024−$1.3M−$21K−$92K−$541K−$1.3M

Bio Key International: income statement and cash flow

Bio Key International, Q2 2026: revenue $1.9M (+13% year over year), operating margin -27.6%. The chart follows the revenue to costs, profit and cash.

Bio Key International: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.